Selcia is a global contract research provider of integrated drug discovery, medicinal chemistry and 14C radiolabeled compounds. Established in 2001, the company has two divisions: Selcia Drug Discovery - with medicinal chemistry,biology ADME and a unique peptidyl proyl isomerase (PPIase) inhibitor screening platform; and Selcia Radiolabeling - one of the world’s largest suppliers of custom 14C radiochemicals.
